for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cosmo Pharmaceuticals NV

COPN.S

Latest Trade

73.80CHF

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

67.20

 - 

128.50

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
73.80
Open
--
Volume
--
3M AVG Volume
0.21
Today's High
--
Today's Low
--
52 Week High
128.50
52 Week Low
67.20
Shares Out (MIL)
14.62
Market Cap (MIL)
1,117.29
Forward P/E
-30.48
Dividend (Yield %)
--

Next Event

Full Year 2019 Cosmo Pharmaceuticals NV Earnings Release

Latest Developments

More

Cosmo Pharmaceuticals H1 Loss Of EUR 20.8 Million

FDA Accepts NDA Filing For Cosmo Pharmaceuticals' Remimazolam

Cosmo Pharmaceuticals: FDA Allowance Of IND Application For CB-03-10

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.

Industry

Biotechnology & Drugs

Contact Info

Riverside II, Sir John Rogerson's Quay

+353.1.8170370

http://www.cosmopharma.com/

Executive Leadership

Mauro Severino Ajani

Chairman of the Board, Non-Executive Director

Alessandro Della Cha

Chief Executive Officer, Executive Director, Member of the Management Board

Niall Donnelly

Chief Financial Officer, Member of the Management Board

Giuseppe Cipriano

Chief Operating Officer, Member of the Management Board

Luigi Moro

Chief Scientific Officer, Member of the Management Board

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.0K
EPS (EUR)

2016

1.370

2017

-2.190

2018

-1.200

2019(E)

-2.213
Price To Earnings (TTM)
--
Price To Sales (TTM)
20.10
Price To Book (MRQ)
2.44
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
40.48
LT Debt To Equity (MRQ)
40.09
Return on Investment (TTM)
-6.09
Return on Equity (TTM)
-5.92

Latest News

Latest News

BRIEF-Cosmo Pharmaceuticals: Canadian Agency Approval Of Eleview

* ELEVIEW(R) WILL BE COMMERCIALIZED IN CANADA BY PENDOPHARM (DIVISION OF PHARMASCIENCE INC.) UNDER AN EXISTING LICENSE AND SUPPLY AGREEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Announces Publication Of Positive Review Of Aemcolo

* ANNOUNCED TODAY PUBLICATION OF A REVIEW OF AEMCOLO IN A CLINICAL INVESTIGATION THAT HIGHLIGHTS ITS SAFETY AND EFFECTIVENESS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-FDA Accepts NDA Filing For Cosmo Pharmaceuticals' Remimazolam

* FDA ACCEPTS FILING OF NDA FOR REMIMAZOLAM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Announces Distribution Agreement And Further Collaboration Agreement

* NEW EXCLUSIVE DISTRIBUTION AGREEMENT FOR ELEVIEW WITH MEDTRONIC IN THE US, CHINA AND SOUTH AMERICA

BRIEF-Cosmo Pharmaceuticals: FDA Allowance Of IND Application For CB-03-10

* FDA Allowance Of IND Application For CB-03-10 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals: Worldwide Distribution Agreement Of AI Device In Colonoscopy With Medtronic

* COSMO PHARMACEUTICALS ANNOUNCES REVOLUTIONARY ARTIFICIAL INTELLIGENCE DEVICE IN COLONOSCOPY TO DETECT LESIONS AND WORLDWIDE DISTRIBUTION AGREEMENT WITH MEDTRONIC Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Announces Submission Of Remimazolam NDA To FDA

* ANNOUNCES SUBMISSION OF REMIMAZOLAM NDA TO FDA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals FY Oper Loss Widens To EUR 16.6 Mln

* FY REVENUE EUR 65.6 MILLION COMPARED TO EUR 67.2 MILLION IN 2017

BRIEF-Cosmo Pharmaceuticals Announces Denial Of Methylene Blue MMX Appeal

* COSMO PHARMACEUTICALS ANNOUNCES DENIAL OF METHYLENE BLUE MMX APPEAL AND BEGINNING OF ACTIVITY TO START SECOND PHASE III TRIAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Files Marketing Authorization Application For Methylene Blue MMX 200 Mg Tablets

* COSMO PHARMACEUTICALS FILES MARKETING AUTHORIZATION APPLICATION FOR METHYLENE BLUE MMX 200 MG TABLETS WITH EUROPEAN MEDICINES AGENCY

BRIEF-Cosmo Pharma Files Marketing Authorization Application For Methylene Blue MMX 200 Mg Tablets With EMA

* COSMO PHARMACEUTICALS FILES MARKETING AUTHORIZATION APPLICATION FOR METHYLENE BLUE MMX 200 MG TABLETS WITH EUROPEAN MEDICINES AGENCY

BRIEF-Cosmo Pharmaceuticals: Regulatory Update For Methylene Blue MMX

* NOW IN PROCESS OF FILING A NEW APPEAL TO OFFICE OF NEW DRUGS (OND), CENTER FOR DRUG EVALUATION AND RESEARCH (CDER) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Launches Offering Of Senior Unsecured Convertible Bonds Due 2023

* LAUNCH OF OFFERING OF SENIOR UNSECURED CONVERTIBLE BONDS DUE 2023

BRIEF-Cosmo Pharmaceuticals: FDA Grants Approval For Aemcolo (Tm) (Rifamycin)

* FDA GRANTS APPROVAL FOR AEMCOLO (TM) (RIFAMYCIN), THE FIRST APPROVED ANTIBIOTIC TO TREAT TRAVELER'S DIARRHEA FOR TEN YEARS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cassiopea Enters Into Loan Agreement With Cosmo Pharmaceuticals

* COSMO PHARMACEUTICALS HAS OFFERED AN UNSECURED CREDIT LINE OF EUR 10 MILLION THAT CAN BE INCREASED TO EUR 20 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Updates On Type A Meeting Outcome For MB MMX

* METHYLENE BLUE MMX REGULATORY UPDATE: TYPE A MEETING OUTCOME

BRIEF-Cosmo Pharmaceuticals H1 Revenue Up 15.2 Pct To EUR 36.7 Million

* H1 REVENUE UP 15.2% TO EUR36.7M DRIVEN BY UP-FRONT LICENSE FEESÂ

BRIEF-Cosmo Pharmaceuticals And Pharmascience Establish License And Supply Agreement

* COSMO PHARMACEUTICALS AND PHARMASCIENCE ESTABLISH LICENSE AND SUPPLY AGREEMENT FOR ELEVIEW, METHYLENE BLUE MMX, RIFAMYCIN MMX AND QOLOTAG FOR CANADA

BRIEF-Cosmo Pharmaceuticals: update on commercialization of Rifamycin SV MMX

* ITS PARTNER DR. FALK PHARMA HAS FILED FOR MARKETING AUTHORIZATION OF RIFAFALK 200MG IN GERMANY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals: update on lawsuit against patent infringement on Uceris

* DISTRICT OF DELAWARE HAS RULED NON-INFRINGEMENT OF ACTAVIS ANDA PRODUCT FOR GENERIC VERSION OF VALEANT’S UCERIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up